News & Insights

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics’ proprietary tined lead design and temperature sensor technology is differentiated from our competitor’s intellect

LOS ANGELES--(BUSINESS WIRE)-- #diagnostics--MedTech Innovator (MTI), the largest accelerator of medical technology companies in the world, today announced that its BioTools Innovator (BTI) accelerator program has been selected as the Enabling Technologies Hub in the next generation of the Biomedical Advanced Research and Development Authority (BARDA) Accelerator Network (BAN). The Network will foster the growth of the health security innovation ecosystem, with particular attention to next-generation medical

LOS ANGELES--(BUSINESS WIRE)--Premium scrub apparel brand Jaanuu has appointed Ian Scherber as its Vice President of Business Development. Scherber brings 15 years of experience in apparel and accessories merchandising. In his new role, Scherber’s primary focus will be launching Jaanuu’s products with new and existing sales channels with the objective of broadening the brand’s reach in wholesale spaces. “I’m excited to help move the brand forward while strengthening our relationships, both new

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genetic and genomic testing, today announced enhancements to their portfolio of tests for the detection of genetic mutations associated with hereditary cancer. This new evidence-informed menu builds on the company’s 12-year history in hereditary cancer testing, to offer tests reflecting the latest scientific evidence and national consensus guidelines. In the United States, an estimated 2 million patients will receive a c

IRVINE, Calif.--(BUSINESS WIRE)-- #BioDuroSundia--BioDuro-Sundia Appoints Dr. Armin Spura as New Chief Executive Officer

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today is sharing a summary of the core issues to consider in this contest for control of the Masimo Board and urging stockholders to vote “FOR” only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card. “For more than 35 years, the team at Masimo has poured our heart and soul into drivin

IRVINE, Calif.--(BUSINESS WIRE)--Masimo is partnering with Qualcomm Technologies to develop a comprehensive reference platform to expand the Wear OS by Google™ ecosystem.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo announced a partnership with Google to develop a comprehensive smartwatch reference platform for OEMs building Wear OS by Google smartwatches.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today issued a statement following two rulings by the U.S. District Court for the Central District of California (“the Court”): one that finds Politan Capital Management LP (“Politan”) and Quentin Koffey are in contempt of court in connection with their September 12, 2024 violation of a court order, and another that finds Poli

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously announced underwritten public offering of 8,093,712 shares of its common stock at a price to the public of $18.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,458,600 additional shares of

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today announced that leading proxy advisory firm Egan-Jones has recommended that stockholders vote on the updated GOLD proxy card “FOR” ONLY Masimo’s director nominees – Joe Kiani and Christopher Chavez – in connection with its September 19, 2024 Annual Meeting of Stockholders (the “Annual Meeting”). In summarizing its positio

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- #Healthcare--MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care. Founded in 1997 and acquired by Terumo Corporation in 2006, M

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today set the record straight in response to Politan Capital Management LP (“Politan”) and Quentin Koffey’s preemptive press release regarding an order from the U.S. District Court for the Central District of California that is still under seal. Masimo’s lawsuit forced Politan to issue several new disclosures, including on the

IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc. today announced that a diverse patient population of over 17,000 has been successfully enrolled in the FLEX Study, a prospective real-world evidence, whole transcriptome, observational breast cancer study (NCT03053193). The FLEX Study, which intends to enroll 30,000 patients, employs a patient-centric design to accelerate impactful data generation through a national network of participating sites. This approach encourages investigator-i

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing of its underwritten public offering of (i) 6,635,112 shares of its common stock at a price to the public of $18.00 per share and (ii) pre-funded warrants to purchase up to an aggregate of 3,088,888 shares of common stock at a price to the public of $17.99 per pre-

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. Xencor also intends to grant the underwriters a 30-day option to purch

IRVINE, Calif.--(BUSINESS WIRE)-- #ClinicalTrials--Immunis, Inc., a clinical-stage biotech developing novel secretome therapeutics for age-related diseases and immune dysfunction, was recently granted permission by the FDA to proceed with its Phase II clinical trial testing its investigational secretome (IMMUNA) in reversing sarcopenic obesity. The news comes shortly after Immunis completed secretome-treatment of its third patient cohort in a Phase I/IIa clinical trial for age-related muscle atrophy (sarcopenia)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, is excited to announce the second wave of intravenous (IV) wellness clinics that will offer pharmaceutical-grade Niagen® (nicotinamide riboside chloride or NRC), branded Niagen+, in intravenous (IV) and injectable forms. This expansion follows the successful debut of limited quantities of Niagen IV and injections in select clinics

IRVINE, Calif.--(BUSINESS WIRE)--Patient Safety Movement Foundation presents 2024 Humanitarian Awards and Lifetime Achievement Award on final day of annual patient safety summit.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, underscoring the importance of stockholders’ vote in determining the future of the Company and value of their investment. Masimo is urging stockholders to vote “FOR” the

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #25thAnniversary--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, proudly announces its 25th anniversary. For a quarter of a century, ChromaDex has been at the forefront of analytical chemistry and scientific innovation, dedicated to unlocking the full potential of NAD+ to promote healthy aging and enhance the quality of life for people around the world. To celebrate this milestone, ChromaDex is

CULVER CITY, Calif.--(BUSINESS WIRE)--Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), today announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced non-small cell lung cancer (NSCLC) being treated with checkpoint inhibitors (CPI). An oral presentation of the data was presented by John Wrangle, M.D., MPH, Associate Professor, Medical University of South Carolina, at the World Congre

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced four new XmAb® programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and

STÄFA, Switzerland & VALENCIA, Calif.--(BUSINESS WIRE)-- #cochlear--Phonak, a leading provider of life-changing hearing solutions, and its sister brand and partner Advanced Bionics (AB), a global leader in cochlear implant technology, proudly sponsor Rally Caps. This heartwarming family film highlights the power of team building, friendship, and breaking down stigmas associated with hearing loss. Written for the screen and directed by Lee Cipolla, Rally Caps is a moving coming-of-age film adapted from the

LOS ANGELES & SINGAPORE--(BUSINESS WIRE)-- #APAC--MedTech Innovator, the largest accelerator of medical technology companies in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the first and only regional association to provide a unified voice for the medical technology industry, today announced that APrevent was named the 2024 MedTech Innovator Asia Pacific Accelerator program Finals Competition Winner and was awarded the USD 175,000 grand prize. The other finalist

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,700 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara

IRVINE, Calif.--(BUSINESS WIRE)--The Patient Safety Movement Foundation opened its 11th annual global summit today at UC Irvine. PSMF Founder Joe Kiani received a special recognition.

PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Cokey Nguyen, Ph.D., Executive Vice President, Chief Scientific & Technical Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 6:3

IRVINE, Calif.--(BUSINESS WIRE)-- #patientmonitoring--Nihon Kohden, a global leader in medical technology, today announced the launch of RemoteSense, a remote patient monitoring solution designed to help healthcare providers to respond to staffing shortages while maintaining high-quality patient care. As healthcare systems face increasing pressure due to staffing shortages and rising patient volumes, RemoteSense offers a practical approach to monitor multiple patients across different locations in near real-time. T

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) has successfully completed the sale of its Critical Care product group to BD (Becton, Dickinson and Company) (NYSE: BDX) for $4.2 billion in an all-cash transaction. The net proceeds from the sale will be used to fund strategic initiatives including the previously announced acquisitions and share repurchases. “Critical Care has made significant contributions to our company and has a long history of innovation. We are grateful to t

THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into definitive agreements for the issuance and sale of 758,900 shares of its common stock at a purchase price of $8.25 per share and the issuance and sale of pre-funded warrants to purc

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company overview on Sept. 9 at H.C. Wainwright's 26th Annual Global Inv. Conf.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Renata Medical, a leader in innovative vascular solutions for young, growing patients, proudly announces a major milestone with the successful implantation of its Minima Growth Stent in the first patient following its recent FDA approval. “Today marks the beginning of something special,” said Dr. Darren Berman, Director of Congenital Interventional Catheterization at Children’s Hospital Los Angeles. “With the very recent FDA approval of Renata Medical's M

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, highlighting critical details about Politan and Quentin Koffey’s plan to take control of Masimo and failure to act in the best interests of all Masimo stockholders. Masim

IRVINE, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced that Matt Thompson, President and CEO, will present at the 22nd Annual Global Morgan Stanley Conference. Fireside chat is scheduled for September 4, 2024, at 11:30 am. About Endologix Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by pr

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no approved treatments in the U.S. PALISADE successfully met its primary endpoint and all multiplicity-controlled key secondary endpoints, including statistically significant reductions in triglycerides (TGs), apolipopr

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that its management will participate in the Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation. About Masimo Masimo (Nasdaq: MASI) is a global technology company that develops and produces a wide array of industry-lead

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Renata Medical today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s first-of-its-kind Minima Growth Stent that’s specifically tailored for neonates, infants, and young children, but also designed to be re-expanded over the course of their growth period. This approval marks a groundbreaking advancement in the care of young children facing congenital heart defects, something pediatric cardiologists around the world hav

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's Global Healthcare Conference on September 6, 2024, in New York City.

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, and March of Dimes, the leading non-profit organization fighting to improve health outcomes for all moms and babies, are launching a partnership to support new parents with babies in the Neonatal Intensive Care Unit (NICU). Between 9 to 13 percent of babies born require a stay in the NICU due to complex medical needs1, and many babies born preterm, with birth defe

IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the “Annual Meeting”) to be held on September 19, 2024, highlighting the Company’s commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company’s

EL SEGUNDO, Calif. & LEXINGTON, Mass.--(BUSINESS WIRE)--KARL STORZ United States, a global leader in Operating Room (OR) integration, has teamed up with FUJIFILM Healthcare Americas Corporation (Fujifilm), a leading provider of endoscopic imaging and endosurgical solutions, to provide comprehensive solutions for endoscopists and surgeons. The companies will jointly market Fujifilm’s industry-leading flexible gastrointestinal (GI) endoscopes along with best-in-class OR integration solutions from

IRVINE, Calif.--(BUSINESS WIRE)--Masimo SET® pulse oximetry is industry leading, clinically proven, and the primary pulse oximetry at all ten top U.S. hospitals.

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth.

LOS ANGELES--(BUSINESS WIRE)-- #entrepreneurship--Next Health, the world's most advanced brand of proactive healthcare centers, is bringing three new health optimization and longevity centers to Dallas through an area development agreement with Medbuild LLC. This expansion is the second installment for Next Health in Texas, following Austin. The first Next Health Dallas location is expected to open in 2025. Medbuild LLC partnered with Next Health to streamline access for the Dallas community to state-of-the-art he

LOS ANGELES--(BUSINESS WIRE)--Automated Industrial Robotics Inc. (“AIR” or the “Company”) today announced the acquisition of Sewtec Automation (“Sewtec”), a leading industrial automation company based in the United Kingdom. The transaction expands AIR’s geographic footprint, strengthens its engineering capabilities and further positions the Company to capitalize on the increasing global demand for manufacturing automation solutions across a diversified customer base. The transaction was funded

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will present new Phase 3 clinical data from the PALISADE study of plozasiran (ARO-APOC3) at the European Society of Cardiology (ESC) Congress 2024, being held in London August 30 through September 2, 2024. The company will also host a virtual analyst and investor event on September 3, 2024, at 8:00 am EDT. Details about the ESC presentation are listed below. European Society of Cardiology C

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same da

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the “Company”), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update. Recent Business Highlights: Obtained CE Mark approval and initiated commercial launch of the vCLAS™ catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at